Callisto Pharmaceuticals Redirects Atiprimod Clinical Development to Treat Rheumatoid Arthritis

NEW YORK--(BUSINESS WIRE)--Callisto Pharmaceuticals, Inc. (OTC BB: CLSP.OB) today announced that it is focusing further development of atiprimod on treatment of rheumatoid arthritis (RA). Atiprimod has demonstrated a favorable clinical safety profile robustly supported by earlier RA studies as well as by recent oncology trials in advanced carcinoid cancer patients, where the drug was dosed at levels and frequencies considerably higher than anticipated for use in RA. Callisto believes that atiprimod holds significant promise as a new class of orally-administered, disease-modifying agent in RA.